In a bold bid to electrify Wall Street and revolutionize how heart disease is diagnosed, Heartflow, a medical technology company riding the wave of artificial intelligence, has filed plans for a $100 million initial public offering, according to a Thursday SEC filing. The company is poised to list on the Nasdaq under the ticker HTFL, with legal firepower from O’Melveny & Myers LLP and Cooley LLP steering the deal.
Based in Mountain View, California, and founded in 2007, Heartflow has already carved out a pioneering niche in non-invasive coronary diagnostics—an area where precision and speed can mean the difference between life and death. Now, it’s preparing to take its AI-powered tech public, backed by a formidable consortium of private equity and venture capital players, including Bain Capital, HealthCor Partners, Wellington Management, and U.S. Venture Partners.
Transforming Heart Disease Detection with Software and AI
Heartflow’s flagship innovation, the Heartflow Platform, marries advanced software algorithms and artificial intelligence to evaluate coronary artery disease (CAD) without the need for invasive procedures. According to its IPO filing, the platform has been used to assess over 400,000 patients as of March 31—a staggering figure that underscores the technology’s clinical adoption.
“Our mission is to dramatically improve cardiovascular care using cutting-edge AI,” the company emphasized in its prospectus.
Unlike traditional stress tests or angiograms, Heartflow’s approach can analyze standard CT scans to generate a 3D model of the heart’s blood flow. The result? Faster, safer, and more accurate diagnosis—a digital revolution in a field still heavily reliant on legacy tools.
